Menu Search
Equities

Surmodics Inc

SU6:BER

Surmodics Inc

Actions
Health CareMedical Equipment and Services
  • Price (EUR)34.40
  • Today's Change-0.40 / -1.15%
  • Shares traded--
  • 1 Year change+10.26%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Surmodics Inc grew revenues 32.65% from 99.95m to 132.58m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -27.27m to -1.54m.
Gross margin74.02%
Net profit margin-1.16%
Operating margin-6.19%
Return on assets-0.76%
Return on equity-1.21%
Return on investment-0.89%
More ▼

Cash flow in USDView more

In 2023, Surmodics Inc increased its cash reserves by 118.02%, or 22.42m. Cash Flow from Financing totalled 18.41m or 13.88% of revenues. In addition the company generated 10.51m in cash from operations while cash used for investing totalled 6.82m.
Cash flow per share0.5176
Price/Cash flow per share76.26
Book value per share8.28
Tangible book value per share3.58
More ▼

Balance sheet in USDView more

Surmodics Inc has a Debt to Total Capital ratio of 19.99%, a lower figure than the previous year's 26.11%.
Current ratio3.98
Quick ratio3.22
Total debt/total equity0.2498
Total debt/total capital0.1999
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		94.20
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.